阿托伐他汀治疗混合型高脂血症的疗效和安全性

The efficacy and safety of atorvastatin in treatment of combined dyslipidemia

目的 评估红惠医药发展公司生产的阿托伐他汀 (Atorvastatin)治疗高脂血症 ,特别是混合型高脂血症的疗效和安全性。方法 试验组 (阿托伐他汀 10mg d) 5 2例和对照组 (舒降之 10mg d) 5 3例 ,进行随机单盲平行对照试验 ,观察两组降脂疗效和不良反应发生情况。结果 经过 8周治疗 ,阿托伐他汀组TC、LDL C、TG和 (TC HDL C) HDL C分别下降 30 % ,40 % ,30 %和 36 % (P <0 .0 1) ,HDL C虽有升高 (5 % ) ,但差异无显著性意义 (P >0 .0 5 )。组间比较 ,阿托伐他汀降LDL C和TG作用明显优于辛伐他汀 (P <0 .0 5 ) ,降TC作用则两组相似。两组不良反应均很轻微和少见。结论 阿托伐他汀 10mg d治疗混合型高脂血症可以明显降低TC、LDL C ,TG和 (TC HDL C) HDL C ;阿托伐他汀降低LDL C和TG的作用大于同剂量辛伐他汀 ;阿托伐他汀的不良反应轻微 ,耐受性好。

Objective To evaluate the efficacy and safety of atorvastatin manufactured by Honghui Medicine Development Co.in hyperlipidemia,especially in combined dyslipidemia.Methods 105 cases with combined dyslipidemia were divided into 2 groups at random.Atorvastatin 10 mg/d was given to 52 cases in one group and simvastatin (Zocor manufactureed by MSD) also 10 mg/d was given to 53 cases in another group.The efficacy and adverse reactions were recorded.Results Eight weeks later,in atorvastatin group,TC,LDL C,TG and (TC HDL C)/HDL C were significantly lowered by 30%,40%,30% and 36% respectively (P< 0.01). The increase in HDL C(5%) was not statistically significant (P>0.05).The atorvastatin was significantly superior to simvastatin in reduction of LDL C and TG (P<0.05),and was similar in reduction of TC.The adverse reactions were mild and relatively rare in both groups.Conclusions Atorvastatin 10 mg/d can significantly lower TC,LDL C,TG and (TC HDL C)/HDL C in combined dyslipidemia.Atorvastatin is superior to simvastatin in lowering LDL C and TG.The adverse reactions of atorvastatin are mild and can be well tolerated.